

Publications CIC-1427 en 2022

Auteurs	Titre	Type	Journal	DOI
Olivier Adotévi , Dewi Vernerey, Pascale Jacoulet, Aurélia Meurisse, Caroline Laheurte , Hamadi Almotlak, Marion Jacquin, Vincent Kaulek,; Laura Boullerot , Marine Malfroy, Emeline Orillard ,Guillaume Eberst, Aurélie Lagrange, ; Laure Favier, Marie Gagnet-Brun,; Ludovic Doucet , Luis Teixeira , Zineb Ghrieb , Anne-Laure Clairet , Yves Guillaume Marie Kroemer , Didier Hocquet, ; Mélanie Moltenis, Samuel Limat Elisabeth Quoix , Céline Mascaux ; Didier Debieuvre , ;Christine Fagnoni-Legat, Christophe Borg; and Virginie Westeel	Safety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptide–Based Vaccine in Patients With Refractory Advanced Non–Small-Cell Lung Cancer: A Phase Ib/Phase IIa De-Escalation Study	Article	Journal of Clinical Oncology	http://dx.doi.org/10.1200/JCO.22.00096
Zineb Ghrieba, Maud Salmona , David Michonneau, Charles De Saisset , Souhil Allaoua, Jean-Jacques Kiladjian , Jérôme Le Goff , Anne Bergeron, Lina Benajiba	Impact of the COVID-19 pandemic on antiviral drug development for other community-acquired respiratory viruses' infections	Article	Thérapie	https://doi.org/10.1016/j.therap.2022.07.010
C.Baldini ; E.Charton ;E.Schultz ; L.Auroy ;A.Italiano; Robert ;E.Coquan ;N.Isambert ;P.Moreau ;S.Le Gouill ;C.Le Tournea ; Z.Ghrieb ;J.J.Kiladjian ;J.P.Delor ;C. GomezRoc ;N.Ve ;F.Barlesi ;T.Lesimpl ;N.Pene ;J.C.Sori ;C.Massard1S.Besle	Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 study	Article	ESMO Open	https://doi.org/10.1016/j.esmoop.2022.100468
Jean-Jacques Kiladjian , Jean-Christophe Ianotto, Juliette Soret , Nabih Maslah, Cendrine Chaffaut, Françoise Boyer perrard, Fiorenza Barraco, Viviane Dubruille, Claude Capron, Amandine Tisserand, Valérie Rolland-Neyret, Zineb Ghrieb , Sylvie Chevret, Isabelle Plo, Marie-Hélène Schlageter, Veronique Meignin , Matthieu Resche-Rigon, Bruno Cassinat	Final Results of Ruxopeg, a Phase 1/2 Adaptive Randomized Trial of Ruxolitinib (Rux) and Pegylated Interferon Alpha (IFNa) 2a in Patients with Myelofibrosis (MF)	Article	Blood	https://doi.org/10.1182/blood-2022-156389

Auteurs	Titre	Type	Journal	DOI
John Mascarenhas, Hélène F. E. Gleitz, Helen T. Chifotides, Claire N. Harrison, Srđan Verstovsek, Alessandro Maria Vannucchi, Raajit K. Rampal, Jean-Jacques Kiladjian , William Vainchenker, Ronald Hoffman, Rebekka K. Schneider & Alan F. List	Biological drivers of clinical phenotype in myelofibrosis	Literature Review	Literature Review Article	DOI: 10.1038/s41375-022-01767-y
Srđan Verstovsek , Haifa Kathrin Al-Ali , John Mascarenhas , Andrew Perkins , Alessandro Maria Vannucchi , Sanjay R Mohan, Bart L Scott , Dariusz Woszczyk , Steffen Koschmieder , Regina García-Delgado, Rejtő László, Jesse S McGreivy, Wayne P Rothbaum & Jean-Jacques Kiladjian	BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis	Article	Future Oncology	https://doi.org/10.2217/fon-2022-0901
Srđan Verstovsek, Jason Gotlib, Alessandro M. Vannucchi, Alessandro Rambaldi, Andreas Reiter, William Shomali, Tracy I. George, Jay L. Patel, Philomena Colucci, Huiling Zhen, Natalia Oliveira, Jean-Jacques Kiladjian	FIGHT-203, an Ongoing Phase 2 Study of Pemigatinib in Patients With Myeloid/Lymphoid Neoplasms (MLNs) With Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLN FGFR1): A Focus on Centrally Reviewed Clinical and Cytogenetic Responses in Previously Treated Patients	Article	Blood	http://dx.doi.org/10.1182/blood-2022-163099
Ruben Mesa, Srđan Verstovsek, Uwe Platzbecker, Vikas Gupta, David Lavie, Pilar Giraldo, Jean-Jacques Kiladjian , Stephen T Oh, Timothy Devos, Francesco Passamonti, Miklos Egyed, Alessandro Vannucchi, Andrzej Pluta, Donal P McLornan, Jun Kawashima, Mei Huang, Bryan Strouse, Claire Harrison	Clinical Outcomes of Myelofibrosis Patients Following Immediate Transition to Momelotinib from Ruxolitinib	Article	Blood	https://doi.org/10.1182/blood-2022-159636
John Mascarenhas, Claire Harrison, Jean-Jacques Kiladjian , Rami S. Komrokji, Steffen Koschmieder, Alessandro M. Vannucchi, Tymara Berry, Denise Redding, Laurie Sherman, Souria Dougherty, Lixian Peng, Libo Sun, Fei Huang, Ying Wan, Faye Feller, Srđan Verstovsek	MYF3001: A Randomized Open Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor	Article	Blood	https://doi.org/10.1182/blood-2022-160364

Auteurs	Titre	Type	Journal	DOI
Srdan Verstovsek, Florian H. Heidel, Valerio De Stefano, Mike Zuurman, Kenneth Bryan, Armita Afsharinejad, Jean-Jacques Kiladjian	Prediction of Resistance to Hydroxyurea Therapy in Patients with Polycythemia Vera: A Machine Learning Study (PV-AIM)	Article	Blood	https://doi.org/10.1182/blood-2022-157268
Vikas Gupta, Abdulraheem Yacoub, Srdan Verstovsek, Ruben Mesa, Claire Harrison, Alessandro M. Vannucchi, Jean-Jacques Kiladjian , H. Joachim Deeg, Salman Fazal, Lynda Foltz, Ryan J. Mattison, Carole B. Miller, Vinod Parameswaran, Patricia Martin-Regueira, Christopher Hernandez, Jia Wang, Moshe Talpaz	Safety and Efficacy of Fedratinib in Patients with Primary (P), Post-Polycythemia Vera (Post-PV), and Post-Essential Thrombocythemia (Post-ET) Myelofibrosis (MF) Previously Treated with Ruxolitinib: Primary Analysis of the FREEDOM Trial	Article	Blood	https://doi.org/10.1182/blood-2022-156669
Sanjay R Mohan, Stephen T Oh, Haris Ali, Anthony M. Hunter, Francesca Palandri, Betty Lamothe, Yi Cui, Francis Seguy, Amanda McBride, Michael Robert Savona, Jean-Jacques Kiladjian , Srdan Verstovsek	A Phase 1/2 Study of INCB000928 As Monotherapy or Combined with Ruxolitinib (RUX) in Patients (Pts) with Anemia Due to Myelofibrosis (MF)	Article	Blood	https://doi.org/10.1182/blood-2022-169210
Nabih Maslah, Blandine Roux, Nina Kaci, Emmanuelle Verger, Rafael Daltro De Oliveira, Hélène Pasquer, Nicolas Gauthier, Juliette Soret , Saravanan Ganesan, Panhong Gou, Frank Ling, Nathalie Parquet, William Vainchenker, Emmanuel Raffoux , Rose Ann Padua, Stephane Giraudier, Alexandre Puissant, Camille Lobry, Jean-Jacques Kiladjian, Bruno Cassinat, Lina Benajiba	JAK Inhibition Mediates Clonal Selection of RAS Pathway Mutations in Myeloproliferative Neoplasms	Article	Blood	https://doi.org/10.1182/blood-2022-167719
Hélène Pasquer, Rafael Daltro De Oliveira, Juliette Soret , Nabih Maslah, Lin-Pierre Zhao, Clemence Marcault, Marine Cazaux, Nicolas Gauthier , Emmanuelle Verger, Nathalie Parquet, William Vainchenker, Emmanuel Raffoux , Stephane Giraudier, Bruno Cassinat, Jean-Jacques Kiladjian, Lina Benajiba	Distinct Clinico-Molecular Arterial and Venous Thrombotic Scoring Systems for MPN Patients Risk Stratification	Article	Blood	https://doi.org/10.1182/blood-2022-160329

Auteurs	Titre	Type	Journal	DOI
<p>JuanG.AbraldesAgustinAlbillosAnnaBaigesJasmohanBajajRafaelBañaresMartaBarrufet Lina Benajiba AnnalisaBerzigottiChristopheBureauVincenzaCalvarusoAndresCardenasGennaroD'AmicoAndreaDe GottardiAlessandraDell'EraAngelsEscorsell JonathanFallowfieldHectorFerralSvenFrancqueRonGabaJuan CarlosGarcia-PagànJoanGenescàSusana GomesRodriguesJordiGracia-SanschoGuohongHanVirginiaHernandez-GeaJidongJiaJean Jacques Kiladjian AleksanderKragWimLalemanVincenzoLa MuraSabelaLensXuefengLuoMattiasMandorferSarwa DarwishMuradValerieParadisDavidPatchSalvatorePianoMassimoPinzaniAureliePlessierMassimoPrimignaniBogdanProcopetPierre EmmanuelRautouMarikaRudlerShiv K.SarinFilippoSchepisMarcoSenzoloVijayShahAkashShuklaPuneetaTandonLuisTellezDominiqueThabutMajaThieleJonelTrebickaDhirajTripathiEmmanouilTsochatzisLauraTurcoFannyTuronDominiqueVallaCandidVillanuevaIwanWanlessHitoshiYoshiji</p>	<p>Corrigendum to 'Baveno VII – Renewing consensus in portal hypertension' [J Hepatol (2022) 959-974]</p>	<p>Article</p>	<p>Journal of Hepatology</p>	<p>http://dx.doi.org/10.1016/j.jhep.2022.03.024</p>
<p>Srdan Verstovsek, Andrew Kuykendall, Ronald Hoffman, Steffen Koschmieder, Francesco Passamonti, Frank Valone, Nishit B. Modi, Sarita Khanna, Paula G. O'Connor, Suneel K. Gupta, Jean-Jacques Kiladjian</p>	<p>Verify: A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera</p>	<p>Article</p>	<p>Blood</p>	<p>https://doi.org/10.1182/blood-2022-163755</p>
<p>Jeanne M. Palmer, Aaron T. Gerds, Claire Harrison, Jean-Jacques Kiladjian, Sarah Buckley, Karisse Roman-Torres, John Mascarenhas, Ruben Mesa</p>	<p>Differential Impact of Thrombocytopenia and Anemia on Myelofibrosis (MF) Symptom Burden</p>	<p>Article</p>	<p>Blood</p>	<p>https://doi.org/10.1182/blood-2022-156702</p>
<p>Stephen T Oh, Srdan Verstovsek, Jason Gotlib, Vikas Gupta, Uwe Platzbecker, Heinz Gisslinger, Timothy Devos, Jean-Jacques Kiladjian, Donal P. McLornan, Andrew Charles Perkins, Maria Laura Fox, Mary Frances McMullin, Adam J Mead, Miklos Egyed, Jiri Mayer, Tomasz Sacha, Jun Kawashima, Mei Huang, Bryan Strouse, Ruben Mesa</p>	<p>Bone Marrow Fibrosis Changes Do Not Correlate with Efficacy Outcomes in Myelofibrosis: Analysis of More Than 300 JAK Inhibitor-Naïve Patients Treated with Momelotinib or Ruxolitinib</p>	<p>Article</p>	<p>Blood</p>	<p>https://doi.org/10.1182/blood-2022-160409</p>

Auteurs	Titre	Type	Journal	DOI
<p>Tiziano Barbui, Alessandra Carobbio, Arianna Ghirardi, Alessandra Iurlo, Valerio De Stefano, Marta Anna Sobas, Elisa Rumi, Elena Maria Elli, Francesca Lunghi, Mercedes Gasior Kabat, Beatriz Cuevas, Paola Guglielmelli, Massimiliano Bonifacio, Monia Marchetti, Alberto Alvarez-Larran, Laura Maria Fox, Marta Bellini, Rosa Daffini, Giulia Benevolo, Gonzalo Carreño, Andrea Patriarca, Haifa Kathrin Al-Ali, Marcio Andrade, Francesca Palandri, Claire Harrison, Maria Angeles Foncillas, Santiago Osorio, Steffen Koschmieder, Elena Magro, Jean-Jacques Kiladjian, Estefanía Bolaños, Florian H. Heidel, Keina Quiroz, Martin Griesshammer, Valentín García Gutiérrez, Alberto Marin Sanchez, Juan Carlos Hernandez Boluda, Emma Lopez Abadia, Giuseppe Carli, Miguel Sagüés, Rajko Kusec, Blanca Xicoy, Margarita Guenova, Begoña Navas, Anna Angona, Edyta Cichocka, Anna Masternak, Daniele Cattaneo, Cristina Bucelli, Silvia Betti, Oscar Borsani, Fabrizio Cavalca, Sara Carbonell, Natalia Curto-Garcia, Lina Benajiba, Alessandro Rambaldi, Alessandro M. Vannucchi</p>	<p>Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)</p>	<p>Article</p>	<p>Blood</p>	<p>https://doi.org/10.1182/blood-2022-158902</p>
<p>Srdan Verstovsek, Stephen T Oh, Jean-Jacques Kiladjian, Uwe Platzbecker, Francesco Passamonti, Aaron T. Gerds, Alessandro M Vannucchi, Donal P. McLornan, Vikas Gupta, Sebastian Grosicki, Haifa Kathrin Al-Ali, David Lavie, Andrew Kuykendall, Sung-Eun Lee, Alessandra Iurlo, Luminita Ocroteala, Jun Kawashima, Rafe Donahue, Bryan Strouse, Ruben Mesa</p>	<p>Transfusion Independence Response As a Potential Surrogate for Overall Survival in Jaki-Experienced Patients with Myelofibrosis from Momentum</p>	<p>Article</p>	<p>Blood</p>	<p>https://doi.org/10.1182/blood-2022-162877</p>

Auteurs	Titre	Type	Journal	DOI
Aaron T. Gerds, Ruben Mesa, Alessandro M Vannucchi, Haifa Kathrin Al-Ali, David Lavie, Andrew Kuykendall, Sebastian Grosicki, Alessandra Iurlo, Yeow Tee Goh, Mihaela Lazaroiu, Miklos Egyed, Maria Laura Fox, Donal P. McLornan, Andrew Charles Perkins, Sung-Soo Yoon, Vikas Gupta, Jean-Jacques Kiladjian , Rafe Donahue, Jun Kawashima, Srdan Verstovsek	Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor	Article	Blood	https://doi.org/10.1182/blood-2022-162783
Jean-Jacques Kiladjian , Françoise Boyer perrard, Kamel Laribi, Jean-Christophe Ianotto, Dana Ranta, Omar Benbrahim, Serge Bologna, Pascale Cony-Makhoul, Alberto Santagostino, Hacene Zerazhi, Abla Slimani, Olivier Fitoussi, Gabriel Etienne	Prospective Follow-up of Patients with Myelofibrosis (MF) and Treated with Ruxolitinib in France: The Rumycup Study	Article	Blood	https://doi.org/10.1182/blood-2022-156628
John Mascarenhas, Aaron T. Gerds, Jean-Jacques Kiladjian , Konstanze Döhner, Sarah Buckley, Jennifer A. Smith, Adam R Craig, Simran Bedi Singh, Srdan Verstovsek, Claire Harrison	PACIFICA: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary or Secondary Myelofibrosis and Severe Thrombocytopenia	Article	Blood	https://doi.org/10.1182/blood-2022-163456
Saravanan Ganesan, Sarah Awan-Toor, Fabien Guidez, Nabih Maslah, Celine Aoun, Panhong Gou, Chloe Guiguen, Juliette Soret , Odonchimeg Ravdan, Valeria Bisio, Nicolas Dulphy, Marie-Hélène Schlageter, Michele Souyri, Stephane Giraudier, Jean-Jacques Kiladjian , Christine Chomienne, Bruno Cassinat	Comprehensive Analysis of Mesenchymal Cells from Myeloproliferative Neoplasm (MPN) Patients Reveals the Role of HOXB7 in Myelofibrosis Induction	Article	Blood	https://doi.org/10.1182/blood-2022-157490
Ruben Mesa, Marina Kremyanskaya, Andrea Patriarca, Vikas Gupta, Francesca Palandri, Timothy Devos, Claire Harrison, Raajit K. Rampal, Moshe Talpaz, Alessandro Vannucchi, Andrew Kuykendall, Jean-Jacques Kiladjian , Srdan Verstovsek, Gozde Colak, Debarshi Dey, John Mascarenhas	Improvement in Individual Symptoms and Total Symptom Score (TSS) and Matching-Adjusted Indirect Comparison (MAIC) Analysis to Compare TSS As a Continuous Endpoint in Patients with Myelofibrosis Treated with Pelabresib in Combination with Ruxolitinib Versus Janus Kinase Inhibitor Monotherapy	Article	Blood	https://doi.org/10.1182/blood-2022-159389

Auteurs	Titre	Type	Journal	DOI
Ruben Mesa, Claire Harrison, Jeanne M. Palmer, Vikas Gupta, Donal P. McLornan, Mary Frances McMullin, Jean-Jacques Kiladjian , Lynda Foltz, Uwe Platzbecker, Maria Laura Fox, Adam J Mead, David M Ross, Stephen T Oh, Andrew Charles Perkins, Michael F. Leahy, Jun Kawashima, Sunhee Ro, Rafe Donahue, Samineh Deheshi, Srdan Verstovsek	The Impact of Momelotinib on Patient Reported Quality of Life for Symptomatic and Anemic Patients with Myelofibrosis: Results from the Phase 3 Momentum Study	Article	Blood	https://doi.org/10.1182/blood-2022-162547
Florian H Heidel, Andrew Charles Perkins, Andreas Reiter, Carl C. Crodel, Caroline Hasselbalch Riley, María Teresa Gómez-Casares, Istvan Takacs, Heiko Becker, Thomas Lehmann, Olga Vinogradova, Kate Burbury, Alessandro M. Vannucchi, Vikas Gupta, Claire Harrison, Marielle Wondergem, Jean-Jacques Kiladjian , Grace Cleary, Angela Zhang, Bruyère Mahuzier, Jagannath Kota, Anirudh Prahallad, David M Ross	Siremadlin, a Human Double Minute-2 (HDM2) Inhibitor, Added to Ruxolitinib after Suboptimal Response to Ruxolitinib Alone in Patients with Myelofibrosis: Results from Part 1 of the Phase 1/2 Adore Study	Article	Blood	https://doi.org/10.1182/blood-2022-158501
Srdan Verstovsek, Ruben Mesa, Vikas Gupta, David Lavie, Viviane Dubruille, Nathalie Cambier, Uwe Platzbecker, Marek Hus, Blanca Xicoy, Stephen T Oh, Jean-Jacques Kiladjian , Alessandro M Vannucchi, Aaron T. Gerds, Miklos Egyed, Jiri Mayer, Tomasz Sacha, Jun Kawashima, Marc Morris, Mei Huang, Claire Harrison	Momelotinib (MMB) Long-Term Safety: Pooled Data from Three Phase 3 Randomized-Controlled Trials (RCTs)	Article	Blood	https://doi.org/10.1182/blood-2022-162543
Claire Harrison, Marina Kremyanskaya, Prithviraj Bose, Vikas Gupta, Raajit K Rampal, Jonathan Lambert, Moshe Talpaz, Alessandro Vannucchi, Andrew Kuykendall, Jean-Jacques Kiladjian , Srdan Verstovsek, Ruben Mesa, Gozde Colak, Sandra Klein, Soumik Dutta, John Mascarenhas	Pelabresib (CPI-0610) As Add-on to Ruxolitinib in Myelofibrosis: Durability of Response and Safety Beyond Week 24 in the Phase 2 MANIFEST Study	Article	Blood	https://doi.org/10.1182/blood-2022-157735
Jean-Jacques Kiladjian , David M Ross, Laura Maria Fogliatto, Lynda Foltz, Lambert Busque, Zhijian Xiao, Florian H. Heidel, Michael Koehler, Giuseppe A. Palumbo, Massimo Breccia, Norio Komatsu, Keita Kiritto, Blanca Xicoy Cirici, Joaquin Martinez-Lopez, Alicia RoVo, Cheryl Petruk, Mike Zuurman, Laura Mirams, Abigail McMillan, Gavin Harper, Claire Harrison	Gaps in the Assessment and Monitoring of Cardiovascular Risk and Psychological Burden in Polycythemia Vera: Landmark 2.0, a Worldwide Health Survey	Article	Blood	https://doi.org/10.1182/blood-2022-162516

Auteurs	Titre	Type	Journal	DOI
<p>Laurence Legros, Françoise Boyer perrard, Dana Ranta, Lydia Roy, Mario Ojeda-Urbe, Stephane Giraudier, Nathalie Parquet, Jean Christophe Ianotto, Mathieu Wemeau, Isabelle Plantier, Franck E. Nicolini, Eric Lippert, Pascale Cony-Makhoul, Fiorenza Barraco, Laure Stalnikiewicz, Frederic Garban, Brigitte Dupriez, Francois Girodon, Anne Brignier, Yazid Arkam, Mathieu Meunier, Chloe James, Valérie Rolland-Neyret, Valerie Ugo, Pierre Morel, Marie C Bene, Jean-Jacques Kiladjian</p>	<p>Impact of the COVID-19 Epidemic on Patients with Myeloproliferative Neoplasia: The French Prospective Observational Study Covim</p>	<p>Article</p>	<p>Blood</p>	<p>https://doi.org/10.1182/blood-2022-156632</p>
<p>Stephen T Oh, Ruben Mesa, Claire Harrison, Prithviraj Bose, Aaron T. Gerds, Mark L. Heaney, Vikas Gupta, Bart L. Scott, Jean-Jacques Kiladjian, Alessandro Lucchesi, Sarah Buckley, Shanthakumar Tyavanagimatt, Karisse Roman-Torres, John Mascarenhas, Srdan Verstovsek</p>	<p>Pacritinib Is a Potent ACVR1 Inhibitor with Significant Anemia Benefit in Patients with Myelofibrosis</p>	<p>Article</p>	<p>Blood</p>	<p>https://doi.org/10.1182/blood-2022-156936</p>
<p>Rosa Ayala, Nieves Lopez, Adi Shacham Abulafia, Maan Alwan, Costas K. Yannakou, Indu Raman, Vincent Ribrag, Chun Yew Fong, Yulia Volchek, Massimiliano Bonifacio, Alessandra Tucci, Jean-Jacques Kiladjian, Henry Chang, Sharmila Das, Bin Wu, Palanikumar Ravindran, Vivian Shan, Guan Wang, Oriana Esposito, Yu Liu, Zariana Nikolova, Christopher Tehlirian, Shodeinde Coker, David Lavie</p>	<p>BMS-986158, a Potent BET Inhibitor, As Monotherapy and in Combination with Ruxolitinib or Fedratinib in Intermediate- or High-Risk Myelofibrosis: First Results from a Phase 1/2 Study</p>	<p>Article</p>	<p>Blood</p>	<p>https://doi.org/10.1182/blood-2022-159476</p>
<p>Jean-Jacques Kiladjian, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, Petr Dulicek, Arpad Illes, Halyna Pylypenko, Lylia Sivcheva, Jiří Mayer, Vera Yablokova, Kurt Krejcy, Victoria Empson, Hans Carl Hasselbalch, Robert Kralovics, Heinz Gisslinger</p>	<p>Efficacy and Safety of Long-Term Ropeginterferon Alfa-2b Treatment in Patients with Low-Risk and High-Risk Polycythemia Vera (PV)</p>	<p>Article</p>	<p>Blood</p>	<p>https://doi.org/10.1182/blood-2022-156889</p>

Auteurs	Titre	Type	Journal	DOI
John Mascarenhas, Marina Kremyanskaya, Andrea Patriarca, Vikas Gupta, Francesca Palandri, Timothy Devos, Raajit K Rampal, Moshe Talpaz, Alessandro Vannucchi, Andrew Kuykendall, Jean-Jacques Kiladjian , Srdan Verstovsek, Ruben Mesa, Gozde Colak, Qing Li, Sandra Klein, Claire Harrison	Pelabresib (CPI-0610) Combined with Ruxolitinib for JAK Inhibitor Treatment-Naïve Patients with Myelofibrosis: Durability of Response and Safety Beyond Week 24	Article	Blood	https://doi.org/10.1182/blood-2022-158147
Tiziano Barbui, Alessandra Carobbio, Arianna Ghirardi, Alessandra Iurlo, Valerio De Stefano, Marta Anna Sobas, Elisa Rumi, Elena Maria Elli, Francesca Lunghi, Mercedes Gasior Kabat, Beatriz Cuevas, Paola Guglielmelli, Massimiliano Bonifacio, Monia Marchetti, Alberto Alvarez-Larran, Laura Fox, Marta Bellini, Rosa Daffini, Giulia Benevolo, Gonzalo Carreno-Tarragona, Andrea Patriarca, Haifa Kathrin Al-Ali, Maria Marcio Miguel Andrade-Campos, Francesca Palandri, Claire Harrison, Maria Angeles Foncillas, Santiago Osorio, Steffen Koschmieder, Elena Magro Mazo, Jean-Jacques Kiladjian , Estefanía Bolaños Calderón, Florian H. Heidel, Keina Quiroz Cervantes, Martin Griesshammer, Valentin Garcia-Gutierrez, Alberto Marin Sanchez, Juan Carlos Hernandez-Boluda, Emma Lopez Abadia, Giuseppe Carli, Miguel Sagues Serrano, Rajko Kusec, Blanca Xicoy Cirici, Margarita Guenova, Begona Navas Elorza, Anna Angona, Edyta Cichocka, Anna Kulikowska de Natęcz, Daniele Cattaneo, Cristina Bucelli, Silvia Betti, Oscar Borsani, Fabrizio Cavalca, Sara Carbonell, Natalia Curto-Garcia, Lina Benajiba , Alessandro Rambaldi & Alessandro Maria Vannucchi	Breakthrough infections in MPN-COVID vaccinated patients	Article	Blood Cancer Journal	http://dx.doi.org/10.1038/s41408-022-00749-8
Francesco Passamontia , Claire N.Harrisonb Ruben A.Mesac Jean-JacquesKiladjian d Alessandro M.VannucchieSrdanVerstovsekf	Anemia in myelofibrosis: Current and emerging treatment options	Literature Review Article	Critical Reviews in Oncology/Hematology	https://doi.org/10.1016/j.critrevonc.2022.103862

Auteurs	Titre	Type	Journal	DOI
Lina Benajiba & Jean-Jacques Kiladjian	Myeloproliferative Neoplasms and Splanchnic Vein Thrombosis	Chapter	In book: Portal Hypertension VII	http://dx.doi.org/10.1007/978-3-031-08552-9_54
Shiv K. Sarin, Dominique-Charles Valla, Anna Baiges, Marta Barrufet, Lina Benajiba, Jean Jacques Kiladjian , Aurelie Plessier, Massimo Primignani & Fanny Turon	Splanchnic Vein Thrombosis: Consensus Statements of Panel 8	Chapter	In book: Portal Hypertension VII	http://dx.doi.org/10.1007/978-3-031-08552-9_55
Ruben Mesa, Aaron Gerds, Alessandro Vannucchi Haifa Kathrin Ali , David Lavie, Andrew Kuykendall, Sebastian Grosicki, Alessandra Iurlo, Yeow Tee Goh Mihaela Lazaroiu, Miklos Egyed, Maria Laura Fox, Donal McLornan Andrew Perkins, Sung-Soo Yoon Vikas Gupta, Jean-Jacques Kiladjian , Rafe Donahue, Jun Kawashima, Srdan Verstovsek	MPN-478 MOMENTUM: Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated With a JAK Inhibitor	Article	Clinical Lymphoma, Myeloma and Leukemia	http://dx.doi.org/10.1016/S2152-2650(22)01463-X
Aaron Gerds , Srdan Verstovsek , Alessandro Vannucchi , Haifa Kathrin Al Ali David Lavie Andrew Kuykendall Sebastian Grosicki , Alessandra Iurlo, Yeow Tee Goh, Mihaela Lazaroiu Miklos Egyed, Maria Laura Fox , Donal McLornan , Andrew Perkins , Sung-Soo Yoon Vikas Gupta Jean-Jacques Kiladjian Rafe Donahue Jun Kawashima Ruben Mesa	MPN-483 Thrombocytopenic Myelofibrosis (MF) Patients Previously Treated With a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) [MOMENTUM]	Article	Clinical Lymphoma, Myeloma and Leukemia	http://dx.doi.org/10.1016/S2152-2650(22)01464-1
John Mascarenhas , Marina Kremyanskaya Andrea Patriarca , Claire Harrison Prithviraj Bose , Raajit K Rampal , Francesca Palandri Timothy Devos Francesco Passamonti MD8 , Gabriela Hobbs , Moshe Talpaz Alessandro Vannucchi Jean-Jacques Kiladjian Srdan Verstovsek Ron Hoffman , Mohamed E Salama, Dong Chen Pietro Taverna , Alex Chang, Gozde Colak Sandra Klein Vikas Gupta	Poster: MPN-375 BET Inhibitor Pelabresib (CPI-0610) Combined With Ruxolitinib in Patients With Myelofibrosis-JAK Inhibitor-Naïve or With Suboptimal Response to Ruxolitinib-Preliminary Data From the MANIFEST Study	Poster	Clinical Lymphoma, Myeloma and Leukemia	https://doi.org/10.1016/S2152-2650(22)00982-X

Auteurs	Titre	Type	Journal	DOI
Vikas Gupta , John Mascarenhas , Marina Kremyanskaya , Raajit K Rampal , Moshe Talpaz , Jean-Jacques Kiladjian , , Alessandro Vannucchi , Srdan Verstovsek , Gozde Colak, Debarshi Dey , Claire Harrison	MPN-379 Matching-Adjusted Indirect Comparison (MAIC) of Pelabresib (CPI-0610) in Combination With Ruxolitinib vs. JAK Inhibitor Monotherapy in Patients With Intermediate or High-Risk Myelofibrosis	Article	Clinical Lymphoma, Myeloma and Leukemia	https://doi.org/10.1016/S2152-2650(22)01457-4
Ruben Mesa, Aaron Gerds, Alessandro Vannucchi Haifa Kathrin Ali , David Lavie, Andrew Kuykendall, Sebastian Grosicki, Alessandra Iurlo, Yeow Tee Goh Mihaela Lazaroiu, Miklos Egyed, Maria Laura Fox, Donal McLornan Andrew Perkins, Sung-Soo Yoon Vikas Gupta, Jean-Jacques Kiladjian , Rafe Donahue, Jun Kawashima, Srdan Verstovsek	Poster: MPN-478 MOMENTUM: Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated With a JAK Inhibitor	Poster	Clinical Lymphoma, Myeloma and Leukemia	http://dx.doi.org/10.1016/S2152-2650(22)00950-8
Vikas Gupta , John Mascarenhas , Marina Kremyanskaya , Raajit K Rampal , Moshe Talpaz , Jean-Jacques Kiladjian , , Alessandro Vannucchi , Srdan Verstovsek , Gozde Colak, Debarshi Dey , Claire Harrison	Poster: MPN-379 Matching-Adjusted Indirect Comparison (MAIC) of Pelabresib (CPI-0610) in Combination With Ruxolitinib vs. JAK Inhibitor Monotherapy in Patients With Intermediate or High-Risk Myelofibrosis	Poster	Clinical Lymphoma, Myeloma and Leukemia	https://doi.org/10.1016/S2152-2650(22)00973-9
Aaron Gerds , Srdan Verstovsek , Alessandro Vannucchi , Haifa Kathrin Al Ali David Lavie Andrew Kuykendall Sebastian Grosicki , Alessandra Iurlo, Yeow Tee Goh, Mihaela Lazaroiu Miklos Egyed, Maria Laura Fox , Donal McLornan , Andrew Perkins , Sung-Soo Yoon Vikas Gupta Jean-Jacques Kiladjian Rafe Donahue Jun Kawashima Ruben Mesa	Poster: MPN-483 Thrombocytopenic Myelofibrosis (MF) Patients Previously Treated With a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) [MOMENTUM]	Poster	Clinical Lymphoma, Myeloma and Leukemia	http://dx.doi.org/10.1016/S2152-2650(22)00951-X

Auteurs	Titre	Type	Journal	DOI
John Mascarenhas , Marina Kremyanskaya Andrea Patriarca , Claire Harrison Prithviraj Bose , Raajit K Rampal , Francesca Palandri Timothy Devos Francesco Passamonti MD8 , Gabriela Hobbs , Moshe Talpaz Alessandro Vannucchi Jean-Jacques Kiladjian Srdan Verstovsek Ron Hoffman , Mohamed E Salama, Dong Chen Pietro Taverna , Alex Chang, Gozde Colak Sandra Klein Vikas Gupta	MPN-375 BET Inhibitor Pelabresib (CPI-0610) Combined With Ruxolitinib in Patients With Myelofibrosis – JAK Inhibitor-Naïve or With Suboptimal Response to Ruxolitinib – Preliminary Data From the MANIFEST Study	Article	Clinical Lymphoma, Myeloma and Leukemia	http://dx.doi.org/10.1016/S2152-2650(22)01456-2
Tiziano Barbui, Alessandra Carobbio, Arianna Ghirardi, Alessandra Iurlo, Marta Anna Sobas, Elena Maria Elli, Elisa Rumi, Valerio De Stefano, Francesca Lunghi, Monia Marchetti, Rosa Daffini, Mercedes Gasior Kabat, Beatriz Cuevas, Maria Laura Fox, Marcio Miguel Andrade-Campos, Francesca Palandri, Paola Guglielmelli, Giulia Benevolo, Claire Harrison, Maria-Angeles Foncillas, Massimiliano Bonifacio, Alberto Alvarez-Larran, Jean-Jacques Kiladjian , Estefanía Bolaños Calderón, Andrea Patriarca, Keina Quiroz Cervantes, Martin Griesshammer, Valentin Garcia-Gutierrez, Alberto Marin Sanchez, Elena Magro Mazo, Giuseppe Carli, Juan Carlos Hernandez-Boluda, Santiago Osorio, Gonzalo Carreno-Tarragona, Miguel Sagues Serrano, Rajko Kusec, Begona Navas Elorza, Anna Angona, Blanca Xicoy Cirici, Emma Lopez Abadia, Steffen Koschmieder, Daniele Cattaneo, Cristina Bucelli, Edyta Cichocka, Anna Kulikowska de Nałęcz, Fabrizio Cavalca, Oscar Borsani, Silvia Betti, Marta Bellini, Natalia Curto-Garcia, Alessandro Rambaldi, Alessandro Maria Vannucchi	Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID-19	CORRESPONDENCE	American Journal of Hematology	https://doi.org/10.1002/ajh.26732
Paola Guglielmelli, Jean-Jacques Kiladjian , Alessandro M. Vannucchi, Minghui Duan, Haitao Meng, Ling Pan, Guangsheng He, Srdan Verstovsek, Françoise Boyer, Fiorenza Barraco, Dietger Niederwieser, Ester Pungolino, Anna Marina Liberati, Claire Harrison, Pantelia Roussou, Monika Wroclawska, Divyadeep Karumanchi, Karen	Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50 × 10 ⁹ /L to <100 × 10 ⁹ /L) at baseline: the final analysis of EXPAND	Article	Therapeutic Advances in Hematology	https://doi.org/10.1177/20406207221118429

Auteurs	Titre	Type	Journal	DOI
Régis Peffault de Latour Jeff Szer MBBS, Ilene C Weitz, Alexander Röth, Britta Höchsmann, Jens Panse, Kensuke Usuki Morag Griffin, Jean-Jacques Kiladjian , Carlos M de Castro, Hisakazu Nishimori, Temitayo Ajayi, Mohammed Al-AdhamiP, Pascal Deschatelets, Cedric Francois, Federico Grossi, Antonio M Risitano, Peter Hillmen, Sinclair, Peter A.W. te Boekhorst, and Heinz Gisslinger	Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial	Article	The Lancet Haematology	http://dx.doi.org/10.1016/S2352-3026(22)00210-1
Christopher J. Patriquin, Andrija Bogdanovic, Morag Griffin, Richard Kelly, Jaroslaw P. Maciejewski, Brian Mulherin, Régis Peffault de Latour , Alexander Roeth, Veena Selvaratnam, Jeffrey Szer, Jessica Savage, Regina Horneff, Lisa Tan, Michael Yeh, Jens Panse	Long-Term Safety and Efficacy of Pegcetacoplan Treatment in Adults with Paroxysmal Nocturnal Hemoglobinuria	Article	Blood	https://doi.org/10.1182/blood-2022-163625
Jun-ichi Nishimura ¹ ; Kensuke Usuki ² ; Julia Ramos ³ ; Satoshi Ichikawa ⁴ ; Muriel Buri ⁵ ; Anna Kiialainen ⁵ Alexandre Sostelly; Régis Peffault de Latour ; Ido Paz-Priel, Alexander Röt	Crovalimab for treatment of patients with paroxysmal nocturnal haemoglobinuria and complement C5 polymorphism: Subanalysis of the phase 1/2 COMPOSER study	Article	BJHaem	https://doi.org/10.1111/bjh.18274
Claire N Harrison, Vikas K Gupta, Aaron T Gerds, Raajit Rampal, Srdan Verstovsek, Moshe Talpaz, Jean-Jacques Kiladjian , Ruben Mesa, Andrew T Kuykendall, Alessandro M Vannucchi, Francesca Palandri, Sebastian Grosicki, Timothy Devos, Eric Jourdan, Marielle J Wondergem, Haifa Kathrin Al-Ali, Veronika Buxhofer-Ausch, Alberto Alvarez-Larrán, Andrea Patriarca, Marina Kremyanskaya, Adam J Mead, Sanjay Akhiani, Yuri Sheikine, Gozde Colak & John Mascarenhas	Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis	Article	Future Oncology	https://doi.org/10.2217/fon-2022-0484
Harrison, Claire ¹ ; Heidel, Florian H. ² ; Vannucchi, Alessandro M. ³ ; Kiladjian, Jean-Jacques ⁴ ; Hayat, Amjad ⁵ ; Passamonti, Francesco ⁶ ; Conneally, Eibhlin ⁷ ; Kindler, Thomas ⁸ ; Martino, Bruno ⁹ ; Lipka, Daniel B. ¹⁰ ; Stefanelli, Tommaso ¹¹ ; Roussou, Pantelia ¹¹ ; Germano, Davide ¹¹ ; Ewan, Jacqueline ¹² ; Ribrag, Vincent ¹³	A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis	Article	HemaSphere	http://dx.doi.org/10.1097/HS9.0000000000000757

Auteurs	Titre	Type	Journal	DOI
<p>Ruben Mesa, Claire Harrison, Stephen T. Oh, Aaron T. Gerds, Vikas Gupta, John Catalano, Francisco Cervantes, Timothy Devos, Marek Hus, Jean-Jacques Kiladjian, Ewa Lech-Maranda, Donal McLornan, Alessandro M. Vannucchi, Uwe Platzbecker, Mei Huang, Bryan Strouse, Barbara Klencke & Srdan Verstovsek</p>	<p>Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis</p>	<p>Article</p>	<p>Leukemia</p>	<p>https://doi.org/10.1038/s41375-022-01637-7</p>
<p>Marta Sobas, Jean-Jacques Kiladjian, Yan Beauverd, Natalia Curto-Garcia, Parvis Sadjadian, Lee Yung Shih, Timothy Devos, Dorota Krochmalczyk, Serena Galli, Maria Bieniaszewska, Ilona Seferynska, Mary Frances McMullin, Anna Armatys, Adrianna Spalek, Joanna Waclaw, Mihnea Zdrengeha, Laurence Legros, François Girodon, Krzysztof Lewandowski, Anna Angona Figueras, Jan Samuelsson, Aitor Abuin Blanco, Pascale Cony-Makhoul, Angela Collins, Chloé James, Rajko Kusec, Marie Lauermannova, Maria Sol Noya, Malgorzata Skowronek, Lukasz Szukalski, Anna Szmigielska-Kaplon, Marielle Wondergem, Iryna Dudchenko, Joanna Gora Tybor, Kamel Laribi, Anna Kulikowska de Nalecz, Jean-Loup Demory, Katell Le Du, Sonja Zweegman, Carlos Besses Raebel, Radek Skoda, Stéphane Giraudier, Martin Griesshammer, Claire N. Harrison, Jean-Christophe Ianotto</p>	<p>Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs</p>	<p>Article</p>	<p>Blood Advances</p>	<p>https://doi.org/10.1182/bloodadvances.2022007201</p>
<p>John Mascarenhas, Claire N Harrison, Jean-Jacques Kiladjian, Rami S Komrokji, Steffen Koschmieder, Alessandro M Vannucchi, Tymara Berry, Denise Redding, Laurie Sherman, Souria Dougherty, Lixian Peng, Libo Sun, Fei Huang, Ying Wan, Faye M Feller, Aleksandra Rizo & Srdan Verstovsek</p>	<p>Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMPactMF phase III study design</p>	<p>Literature Review Article</p>	<p>Future Oncology</p>	<p>https://doi.org/10.2217/fon-2022-0235</p>

Auteurs	Titre	Type	Journal	DOI
<p>Daniel A. Arber, Attilio Orazi, Robert P. Hasserjian, Michael J. Borowitz, Katherine R. Calvo, Hans-Michael Kvasnicka, Sa A. Wang, Adam Bagg, Tiziano Barbui, Susan Branford, Carlos E. Bueso-Ramos, Jorge E. Cortes, Paola Dal Cin, Courtney D. DiNardo, Hervé Dombret, Eric J. Duncavage, Benjamin L. Ebert, Elihu H. Estey, Fabio Facchetti, Kathryn Foucar, Naseema Gangat, Umberto Gianelli, Lucy A. Godley, Nicola Gökbuget, Jason Gotlib, Eva Hellström-Lindberg, Gabriela S. Hobbs, Ronald Hoffman, Elias J. Jabbour, Jean-Jacques Kiladjian, Richard A. Larson, Michelle M. Le Beau, Mignon L.-C. Loh, Bob Löwenberg, Elizabeth Macintyre, Luca Malcovati, Charles G. Mullighan, Charlotte Niemeyer, Olatoyosi M. Odenike, Seishi Ogawa, Alberto Orfao, Elli Papaemmanuil, Francesco Passamonti, Kimmo Porkka, Ching-Hon Pui, Jerald P. Radich, Andreas Reiter, Maria Rozman, Martina Rudelius, Michael R. Savona, Charles A. Schiffer, Annette Schmitt-Graeff, Akiko Shimamura, Jorge Sierra, Wendy A. Stock, Richard M. Stone, Martin S. Tallman, Jürgen Thiele, Hwei-Fang Tien, Alexandar Tzankov, Alessandro M. Vannucchi, Paresh Vyas, Andrew H. Wei, Olga K. Weinberg, Agnieszka Wierzbowska, Mario Cazzola, Hartmut Döhner, Ayalew Tefferi</p>	<p>International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data</p>	<p>Article</p>	<p>Blood</p>	<p>https://doi.org/10.1182/blood.2022015850</p>
<p>Aaron Thomas Gerds, Srdan Verstovsek, Alessandro Vannucchi, Haifa Kathrin Al-Ali, David Lavie, Andrew T. Kuykendall, Sebastian Grosicki, Alessandra Iurlo, Yeow Tee Goh, Mihaela Cornelia Lazaroiu, Miklos Egyed, Maria Laura Fox, Donal P. McLornan, Andrew Perkins, Sung-Soo Yoon, Vikas Gupta, Jean-Jacques Kiladjian, Rafe Donahue, Jun Kawashima, Ruben A. Mesa</p>	<p>Thrombocytopenic myelofibrosis (MF) patients previously treated with a JAK inhibitor in a phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) [MOMENTUM]</p>	<p>Article</p>	<p>Journal of Clinical Oncology</p>	<p>http://dx.doi.org/10.1200/JCO.2022.40.16_suppl.7061</p>

Auteurs	Titre	Type	Journal	DOI
Jean-Jacques Kiladjian, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, Petr Dulicek, Arpad Illes, Halyna Pylypenko, Lylia Sivcheva, Jiří Mayer, Vera Yablokova, Kurt Krejcy, Victoria Empson, Hans C. Hasselbalch, Robert Kralovics, Heinz Gisslinger & the PROUD-PV Study Group	Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b	Article	Leukemia	http://dx.doi.org/10.1038/s41375-022-01528-x
Tariq I. Mughal, Naveen Pemmaraju, Rafael Bejar, Robert P. Gale, Prithviraj Bose, Jean-Jacques Kiladjian, Josef Prchal, Daniel Royston, Daniel Pollyea, Peter Valent, Tim H. Brümmendorf, Tomasz Skorski, Mrinal Patnaik, Valeria Santini, Pierre Fenaux, Nicole Kucine, Srdan Verstovsek, Ruben Mesa, Tiziano Barbui, Guiseppe Saglio, Richard A. Van Etten	Perspective Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies	Literature Review Article	Hematological Oncology	https://doi.org/10.1002/hon.2987
Claire N. Harrison, Nicolaas Schaap, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, Francesco Passamonti, Sonja Zweegman, Moshe Talpaz, Srdan Verstovsek, Shelonitda Rose, Jun Zhang, Oumar Sy, Ruben A. Mesa	Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts	Article	British Journal of Haematology	https://doi.org/10.1111/bjh.18207
Monia Marchetti, Alessandro Maria Vannucchi, Martin Griesshammer, Claire Harrison, Steffen Koschmieder, Heinz Gisslinger, Alberto Álvarez-LarránMDgValerioDe Stefano, PaolaGuglielmelli, Francesca Palandri,Francesco Passamonti, Giovanni Barosi, Richard TSilver, Rüdiger Hehlmann, Jean-Jacques Kiladjian, Tiziano Barbui	Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations	Literature Review Article	The Lancet Haematology	http://dx.doi.org/10.1016/S2352-3026(22)00046-1
Graciela Rabadan Moraes, Florence Pasquier, Christophe Marzac, Eric Deconinck, Carlotta Caterina Damanti, Gwendoline Leroy, Mira El-Khoury, Wassim El Nemer, Jean-Jacques Kiladjian, Hana Raslova, Albert Najman, William Vainchenker, Caroline Marty, Christine Bellanné-Chantelot, Isabelle Plo	An inherited gain-of-function risk allele in EPOR predisposes to familial JAK2V617F myeloproliferative neoplasms	Article	British Journal of Haematology	http://dx.doi.org/10.1111/bjh.18165

Auteurs	Titre	Type	Journal	DOI
Tiziano Barbui, Alessandra Iurlo, Arianna Masciulli, Alessandra Carobbio, Arianna Ghirardi, Greta Carioli, Marta Anna Sobas, Elena Maria Elli, Elisa Rumi, Valerio De Stefano, Francesca Lunghi, Monia Marchetti, Rosa Daffini, Mercedes Gasior Kabat, Beatriz Cuevas, Maria Laura Fox, Marcio Miguel Andrade-Campos, Francesca Palandri, Paola Guglielmelli, Giulia Benevolo, Claire Harrison, Maria Angeles Foncillas, Massimiliano Bonifacio, Alberto Alvarez-Larran, Jean-Jacques Kiladjian , Estefanía Bolaños Calderón, Andrea Patriarca, Keina Quiroz Cervantes, Martin Griessammer, Valentin Garcia-Gutierrez, Alberto Marin Sanchez, Elena Magro Mazo, Marco Ruggeri, Juan Carlos Hernandez-Boluda, Santiago Osorio, Gonzalo Carreno-Tarragona, Miguel Sagues Serrano, Rajko Kusec, Begona Navas Elorza, Anna Angona, Blanca Xicoy Cirici, Emma Lopez Abadia, Steffen Koschmieder, Daniele Cattaneo, Cristina Bucelli, Edyta Cichocka, Anna Masternak Kulikowska de Nałęcz, Fabrizio Cavalca, Oscar Borsani, Silvia Betti, Lina Benajiba , Marta Bellini, Natalia Curto-Garcia, Alessandro Rambaldi & Alessandro Maria Vannucchi	Second versus first wave of COVID-19 in patients with MPN	Article	Leukemia	http://dx.doi.org/10.1038/s41375-022-01507-2
Nabih Maslah, Emmanuelle Verger, Stéphane Giraudier, Mathias Chea, Ronald Hoffman, John Mascarenhas, Bruno Cassinat , Jean-Jacques Kiladjian	Single-cell analysis reveals selection of TP53 - mutated clones after MDM2 inhibition	Article	Blood Advances	https://doi.org/10.1182/bloodadvances.2021005867
Andrew T. Kuykendall, Libo Sun, John Mascarenhas, Jean-Jacques Kiladjian , Alessandro M. Vannucchi, Julia Wang, Qi Xia, Eugene Zhu, Faye Feller, Aleksandra Rizo, Jacqueline Bussolari, Ying Wan & Rami Komrokji	Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data	Article	Annals of Hematology	https://doi.org/10.1007/s00277-021-04683-w

Auteurs	Titre	Type	Journal	DOI
John Mascarenhas, Heidi E. Kosiorek, Josef T. Prchal, Alessandro Rambaldi, Dmitry Berenzon, Abdulraheem Yacoub, Claire N. Harrison, Mary Frances McMullin, Alessandro M. Vannucchi, Joanne Ewing, Casey L. O'Connell, Jean-Jacques Kiladjian , Adam J. Mead, Elliott F. Winton, David S. Leibowitz, Valerio De Stefano, Murat O. Arcasoy, Craig M. Kessler, Rosalind Catchatourian, Damiano Rondelli, Richard T. Silver, Andrea Bacigalupo, Arnon Nagler, Marina Kremyanskaya, Max F. Levine, Juan E. Arango Ossa, Erin McGovern, Lonette Sandy, Mohamad E. Salama, Vesna Najfeld, Joseph Tripodi, Noushin Farnoud, Alexander V. Penson, Rona Singer Weinberg, Leah Price, Judith D. Goldberg, Tiziano Barbui, Roberto Marchioli, Gianni Tognoni, Raajit K. Rampal, Ruben A. Mesa, Amylou C. Dueck, Ronald Hoffman	A randomized phase 3 trial of interferon- α vs hydroxyurea in polycythemia vera and essential thrombocythemia	Article	Blood	https://doi.org/10.1182/blood.202101.2743
Delphine Réa 1, Michael J Mauro 2, Carla Boquimpani 3 4, Yosuke Minami 5, Elza Lomaia 6, Sergey Voloshin 7, Anna Turkina 8, Dong-Wook Kim 9, Jane F Apperley 10, Andre Abdo 11, Laura Maria Fogliatto 12, Dennis Dong Hwan Kim 13, Philipp le Coutre 14, Susanne Saussele 15, Mario Annunziata 16, Timothy P Hughes 17, Naeem Chaudhri 18, Koji Sasaki 19, Lynette Chee 20, Valentin García-Gutiérrez 21, Jorge E Cortes 22, Paola Aimone 23, Alex Allepuz 23, Sara Quenet 23, Véronique Bédoucha 23, Andreas Hochhaus 24	EE360 Health Care Resource Utilization With Asciminib and Bosutinib Among Adults With Chronic Myeloid Leukemia in Chronic Phase Previously Treated With ≥ 2 Tyrosine Kinase Inhibitors: Week 48 and Week 96 Results From ASCSEMBL Trial	Article	Blood	https://doi.org/10.1016/j.jval.2022.09.606
Timothy Hughes, Delphine Rea , Carla Boquimpani, Yosuke Minami, Michael Mauro, Jorge E. Cortes, Jane F. Apperley, Valentín García Gutiérrez, Shruti Kapoor, Alex Allepuz, Sarah Quenet, Yifan Zhang, Andreas Hochhaus	Dynamics of Response and Response Factors in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥ 2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 Ascembl Study	Article	Blood	https://doi.org/10.1182/blood-2022-169110

Auteurs	Titre	Type	Journal	DOI
<p>Delphine Réa, Andreas Hochhaus, Michael J. Mauro, Yosuke Minami, Elza Lomaia, Sergey Voloshin, Anna Turkina, Dong-Wook Kim, Jane F. Apperley, Jorge E. Cortes, AndreAbdo, Laura Marie Fogliatto, Dennis Dong Hwan Kim, Philipp le Coutre, Susanne Saussele, Mario Annunziata, Timothy P. Hughes, Naeem Chaudhri, Lynette Chee, Valentin García-Gutiérrez, Koji Sasaki, Shruti Kapoor, Alex Allepuz, Sara Quenet, Véronique Bédoucha, Carla Boquimpani</p>	<p>Poster: CML-395 Efficacy and Safety Results From ASCEMBL, a Phase III Study of Asciminib vs. Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): Week 96 Update</p>	<p>Poster</p>	<p>Clinical Lymphoma, Myeloma and Leukemia</p>	<p>http://dx.doi.org/10.1016/S2152-2650(22)00881-3</p>
<p>Delphine Réa, Andreas Hochhaus, Michael J. Mauro, Yosuke Minami, Elza Lomaia, Sergey Voloshin, Anna Turkina, Dong-Wook Kim, Jane F. Apperley, Jorge E. Cortes, AndreAbdo, Laura Marie Fogliatto, Dennis Dong Hwan Kim, Philipp le Coutre, Susanne Saussele, Mario Annunziata, Timothy P. Hughes, Naeem Chaudhri, Lynette Chee, Valentin García-Gutiérrez, Koji Sasaki, Shruti Kapoor, Alex Allepuz, Sara Quenet, Véronique Bédoucha, Carla Boquimpani</p>	<p>CML-395 Efficacy and Safety Results From ASCEMBL, a Phase III Study of Asciminib vs. Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): Week 96 Update</p>	<p>Article</p>	<p>Clinical Lymphoma, Myeloma and Leukemia</p>	<p>https://doi.org/10.1016/S2152-2650(22)01379-9</p>
<p>Rea, D; Hochhaus, ; Mauro, M; Minami ; Lomaia ; Voloshin,; Turkina, Kim, D.-W.; Apperley, J. ; Cortes, J. ; Abdo,; Fogliatto, ; Kim, D. ; le Coutre,; Saussele, ; Annunziata, ; Hughes, T. ; Chaudhri, ; Chee; García-Gutiérrez, ; Sasaki, ; Kapoor; Allepuz; Quenet; Bédoucha; Boquimpani</p>	<p>S155: EFFICACY AND SAFETY RESULTS FROM ASCEMBL, A PHASE 3 STUDY OF ASCIMINIB VS BOSUTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE AFTER ≥2 PRIOR TYROSINE KINASE INHIBITORS: WK 96 UPDATE</p>	<p>ORAL SESSIONS</p>	<p>HemaSphere</p>	<p>DOI: 10.1097/01.HS9.0000843512.62237</p>
<p>Delphine Rea, Michael J. Mauro, Andreas Hochhaus, Carla Boquimpani, Elza Lomaia, Sergey Voloshin, Anna G. Turkina, Dong-Wook Kim, Jane Apperley, Jorge E. Cortes, Koji Sasaki, Shruti Kapoor, Alex Allepuz, Sara Quenet, Véronique Bédoucha, Yosuke Minami</p>	<p>Efficacy and safety results from ASCEMBL, a phase 3 study of asciminib versus bosutinib (BOS) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs): Week 96 update.</p>	<p>Article</p>	<p>Journal of Clinical Oncology</p>	<p>http://dx.doi.org/10.1200/JCO.2022.40.16_suppl.7004</p>

Auteurs	Titre	Type	Journal	DOI
Delphine Réa , Timothy P.Hughes	Development of Asciminib, a Novel Allosteric Inhibitor of BCR-ABL1	Literature Review Article	Critical Reviews in Oncology/Hematology	https://doi.org/10.1016/j.critrevonc.2022.103580
Thomas Eigentler ¹ , Igor Samoylenko ² , Sebastian Ochsenreither ³ , Erika Richtig ⁴ , Ioannis Thomas ⁵ , Michael Erdmann ⁶ , Celeste Lebbe , Juan José Soto-Castillo ⁸ , Patrick Terheyden ⁹ , Artem Poltoratskiy ¹⁰ , Marina Sekacheva ¹¹ , Yuliya Semiletova ¹² , Janina Henze ¹³ , Beate Schmitt-Bormann ¹³ , Paula Codó ¹³ , Martin Falk ¹³ and Ulrike Gnad-Vogt ¹³	786 Intratumorally administered CV8102 in patients with advanced solid tumors: preliminary results from ongoing expansion part in study 008	Conference Paper	Journal for ImmunoTherapy of Cancer	http://dx.doi.org/10.1136/jitc-2022-SITC2022.0786
Marina Gonzalez ¹ , Peter Wengenmayer ¹ , Igor Samoylenko ² , Sebastian Ochsenreither ³ , Erika Richtig ⁴ , Ioannis Thomas ⁵ , Michael Erdmann ⁶ , Celeste Lebbe ⁷ , Juan Martin-Liberal ⁸ , Patrick Terheyden ⁹ , Artem Poltoratskiy ¹⁰ , Marina Sekacheva ¹¹ , Yuliya Semiletova ¹² , Thomas Eigentler ¹³ , Beate Schmitt-Bormann ¹ , Dominik Vahrenhorst ¹ , Sarah-Katharina Kays ¹ , Tobias Seibel ¹³ , Gianluca Quintini ¹ , Birgit Scheel ¹ , Martin Falk ¹ , Ulrike Gnad-Vogt ¹ and Paula Codó ¹	784 Immune profiling of patients with advanced melanoma intratumorally treated with CV8102 as a single-agent or in combination with anti-PD-1 antibodies – results of a phase I trial expansion	Conference Paper	Journal for ImmunoTherapy of Cancer	http://dx.doi.org/10.1136/jitc-2022-SITC2022.0784
Sandra D'Angelo ¹ , Celeste Lebbé ² , Laurent Mortier ³ , Andrew Brohl ⁴ , Nicola Fazio ⁵ , Jean-jaques Grob ⁶ , Natalie Prinzi ⁷ , Glenn Hanna ⁸ , Jessica Hassel ⁹ , Felix Kiecker ¹⁰ , Anja von Heydebreck ¹¹ , Gülseren Güzel ¹¹ and Paul Nghiem ¹²	604 First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from the JAVELIN Merkel 200 trial	Conference Paper	Journal for ImmunoTherapy of Cancer	DOI: 10.1136/jitc-2022-SITC2022.0604
Celeste Lebbé , Lucie Biard, Julie Delyon , Julien Zuber	Managing immune checkpoint inhibition in transplant recipients	Article	The Lancet Oncology	http://dx.doi.org/10.1016/S1470-2045(22)00395-3

Auteurs	Titre	Type	Journal	DOI
Marie Véronab Sylvie Chevretec Jean-Jacques Grobdu Marie Beylot Barry, Philippe Saiag, Aude Flécho, Benoit You, Eve Maubec, Thomas Jouary, Elise Toulemonde, Philippe Jamme, Laëtitia Gambotti, Assia Lamrani-Ghaout, Alain Dupu, Céleste Lebbe , Nicole Basset Seguin, Nadine Houede , Marie-Thérèse Leccia, FannyLe D, Michelde Pontville, Caroline Gaudy-Marquestre, Bernard Guillot, Clotilde Simonl Aurélien Marabelle, Laurent Mortier	Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial	Article	European journal of cancer (Oxford, England: 1990)	https://doi.org/10.1016/j.ejca.2022.09.013
Michael K.Wong 1Melissa Burgess2 Sunandana Chandra, Dirk Schadendorf, Ann Silk, Anthony J.Olszanski, Jean-Jacques Grob, Sekwon Jang8, Jaspreet Singh Grewal, Karl D.Lewis, Leslie Fecher, Guilherme Rabinowits, Celeste Lebbe , Juan Martin-Liberal, Anna Maria Di Giacomo, Philip Friedlander, Andrew S.Brohl, Brandon Croft, Jesse S.Mc Greivy, Wayne P.Rothbaum, Ciara M.Kelly	Navtemadlin (KRT-232) in combination with avelumab for patients with anti-PD-1/L1 treatment-naïve TP53WT Merkel cell carcinoma (MCC)	Article	Journal of Investigative Dermatology	https://doi.org/10.1016/j.jid.2022.08.027
Paolo A. Ascierto , Mario Mandalà , Pier Franceso Ferrucci ,; Massimo Guidoboni ,; Piotr Rutkowski ,; Virginia Ferraresi,; Ana Arance ,; Michele Guida,; Evaristo Maiello,; Helen Gogas ,; Erika Richtig ,; Maria Teresa Fierro, Celeste Lebbè ,; Hildur Helgadóttir,; Paola Queirolo,; Francesco Spagnolo, MD, Marco Tucci ,; Michele Del Vecchio,; Maria Gonzales Cao ,; Alessandro Marco Minisini,; Sabino De Placido, Miguel F. Sanmamed ,; Domenico Mallardo ,; Marcello Curvietto,; Ignacio Melero, Giuseppe Palmieri,; Antonio M. Grimaldi ,; Diana Giannarelli ,; Reinhard Dummer , and Vanna Chiarion Sileni ,	Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF - Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial	Article	Journal of Clinical Oncology	http://dx.doi.org/10.1200/JCO.21.02961

Auteurs	Titre	Type	Journal	DOI
Ines Pires da Silva Danny Zakria,Tasnia Ahmed, Claudia Trojanello, Florentia Dimitriou,6 Clara Allayous, Camille Gerard, Lisa Zimmer, Serigne Lo , Olivier Michielin, Celeste Lebbe ,Johanna Mangana, Paolo Antonio Ascierto , Douglas B Johnson, Matteo Carlino, Alexander Menzies, Georgina Long,	Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma	Article	Journal for ImmunoTherapy of Cancer	DOI: 10.1136/jitc-2022-004610
Prachi Bhave , Tasnia Ahmed, Serigne N Lo , Alexander Shoushtari , Anne Zaremba, Judith M Versluis,6 Joanna Mangana,7 Michael Weichenthal , Lu Si, Thierry Lesimple, Caroline Robert , Claudia Trojanello, Alexandre Wicky,Richard Heywood, Lena Tran, Kathleen Batty, Florentia Dimitriou, Anna Stansfeld, Clara Allayous, Julia K Schwarze ,Meghan J Mooradian , Oliver Klein , Inderjit Mehmi, Rachel Roberts-Thomson, Andrea Maurichi,Hui-Ling Yeoh,Adnan Khattak,Lisa Zimmer, Christian U Blank, Egle Ramelyte,7 Katharina C Kähler,Severine Roy,Paolo A Ascierto Olivier Michielin,13 Paul C Lorigan, Douglas B Johnson,15 Ruth Plummer, Celeste Lebbe , Bart Neyns , Ryan Sullivan ,19 Omid Hamid, Mario Santinami, Grant A McArthur,Andrew M Haydon, Georgina V Long, Alexander M Menzies,Matteo S Carlino	Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma	Article	Journal for ImmunoTherapy of Cancer	http://dx.doi.org/10.1136/jitc-2022-004668
Claus Garbea, Teresa Amarala, Ketty Perisbc, Axel Hauschildd ,Petr Arenbergere, Nicole Basset-Seguinf ,Lars Bastholtg ,Veronique Batailleh Veroniqueedel Marmoli Brigitte Drénoy Maria C.FargnolikAna Maria Forseal Jean-Jacques Grobm Christoph Hoellern Roland Kaufmanno Nicole Kelleners-Smeetsp Aimilios Lallasq Celeste Lebbéf Bodhan Lytvynen korJosep Malvehy, Paul Loriganab	European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022	Literature Review Article	European journal of cancer (Oxford, England: 1990)	https://doi.org/10.1016/j.ejca.2022.04.018

Auteurs	Titre	Type	Journal	DOI
Filippo de Braud; Christophe Doooms; Rebecca S. Heist; Celeste Lebbe ; Martin Wermke; David Planchard; Dirk Schadendorf; Piotr Rutkowski; Jürgen Wolf; Paolo A. Ascierto; Ignacio Gil-Bazo; Shumei Kato; Maria Wolodarski; Meredith McKean; Eva Muñoz Couselo; Martin Sebastian; Armando Santoro; Vesselina Cooke; Luca Manganelli; Kitty Wan; Anil Gaur; Tanay S. Samant; Jaeyeon Kim; Giordano Caponigro; Xuân-Mai Couillebault; Michele Moschetta; Adil Daud	Abstract CT197: Phase Ib study of LXH254 + trametinib (TMT) in patients (pts) with NRAS-mutant melanoma	Article	Cancer Research	http://dx.doi.org/10.1158/1538-7445.AM2022-CT197
Paolo Antonio Ascierto, Mario Mandalà, Pier Francesco Ferrucci, Massimo Guidoboni, Piotr Rutkowski, Virginia Ferraresi, Ana Maria Arance, Michele Guida, Evaristo Maiello, Helen Gogas, Erika Richtig, Maria Teresa Fierro, Celeste Lebbe , Hildur Helgadóttir, Ignacio Melero Bermejo, Giuseppe Palmieri, Diana Giannarelli, Antonio Maria Grimaldi, Reinhard Dummer, Vanna Chiarion-Sileni	Phase II study SECOMBIT (sequential combo immuno and target therapy study): A subgroup analysis with a longer follow-up.	Meeting Abstract 2022 ASCO Annual Meeting I	Journal of Clinical Oncology	http://dx.doi.org/10.1200/JCO.2022.40.16_suppl.9535
Claus Garbea, Teresa Amarala, Ketty Perisbc, Axel Hauschildd ,Petr Arenbergere, Nicole Basset-Seguinf ,Lars Bastholtg ,Veronique Batailleh Veronique del Marmoli Brigitte Dréno j Maria C.FargnolikAna Maria Forseal Jean-Jacques Grobm Christoph Hoellern Roland Kaufmanno Nicole Kelleners-Smeetsp Aimilios Lallasq Celeste Lebbe f Bodhan Lytvynen korJosep Malvehy, Paul Loriganab	European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022	Literature Review Article	European Journal of Cancer	https://doi.org/10.1016/j.ejca.2022.03.008
Alexandra Landras, Coralie Reger de Moura, Bruno O. Villoutreix, Maxime Battistella , Aurélié Sadoux , Nicolas Dumaz, Suzanne Menashi, Juan Fernández-Recio, Céleste Lebbe & Samia Mourah	Novel treatment strategy for NRAS-mutated melanoma through a selective inhibitor of CD147/VEGFR-2 interaction	Article	Oncogene	http://dx.doi.org/10.1038/s41388-022-02244-7

Auteurs	Titre	Type	Journal	DOI
<p>Hyacinthe Johnson-Ansah 1,†, Benjamin Maneglier 2,†, Françoise Huguet 3, Laurence Legros 4, Martine Escoffre-Barbe 5, Martine Gardembas 6, Pascale Cony-Makhoul 7, Valérie Coiteux 8, Laurent Sutton 9, Wajed Abarah 10, Camille Pouaty 11, Jean-Michel Pignon 12, Bachra Choufi 13, Sorin Visanica 14, Bénédicte Deau 15, Laure Morisset 16, Emilie Cayssials 17, Mathieu Molimard 18, Stéphane Bouchet 18, François-Xavier Mahon 19, Franck Nicolini 20, Philippe Aegerter 21, Jean-Michel Cayuela 22, Marc Delord 16, Heriberto Bruzzoni-Giovanelli and Philippe Rousselot</p>	<p>Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia</p>	<p>Article</p>	<p>Pharmaceutics</p>	<p>https://doi.org/10.3390/pharmaceutics14081676</p>